Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

ABSTRACT Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy...

Full description

Saved in:
Bibliographic Details
Published inCell biochemistry and function Vol. 42; no. 8; pp. e70011 - n/a
Main Authors Li, Chen Lu, Ma, Xin Yuan, Yi, Ping
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.12.2024
Subjects
Antibodies
Antibodies, Bispecific - immunology
Antibodies, Bispecific - pharmacology
Antibodies, Bispecific - therapeutic use
antibody−drug conjugates
Anticancer properties
Antigen (tumor-associated)
Antitumor activity
Bispecific antibodies
Cancer
Cancer immunotherapy
Conjugates
Conjugation
CTLA-4 protein
Drug development
Effectiveness
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - pharmacology
Immune Checkpoint Inhibitors - therapeutic use
Immune response
Immunoconjugates - pharmacology
Immunoconjugates - therapeutic use
Immunosuppressive agents
Immunotherapy
In vivo methods and tests
Inhibitors
Monoclonal antibodies
Neoplasms - drug therapy
Neoplasms - immunology
Neoplasms - therapy
PD-L1 protein
Pembrolizumab
Side effects
Solid tumors
tumor heterogeneity
antibody−drug conjugates
immune checkpoint inhibitors
bispecific antibodies
monoclonal antibodies
tumor heterogeneity
Online AccessGet full text
ISSN0263-6484
1099-0844
1099-0844
DOI10.1002/cbf.70011

Cover

Abstract ABSTRACT Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy. Immune checkpoints are antibodies targeting PD‐1, PD‐L1, and CTLA4 and have demonstrated remarkable therapeutic efficacy in the treatment of hematological and solid tumors, whose combination therapies have been shown to synergistically enhance the antitumor effects of BsAbs. In addition, the clinical efficacy of existing monoclonal antibodies targeting PD‐1 (e.g., ipilimumab, nivolumab, pembrolizumab, and cemiplimab) and PD‐L1 (e.g., atezolizumab, avelumab, and durvalumab) could also be enhanced by conjugation to small drugs as antibody−drug conjugates (ADCs). The development of truly effective therapies for patients with treatment‐resistant cancers can be achieved by optimizing the various components of ADCs. Summary As the role of engineered antibodies in the development of various immunotherapeutic agents is now well established in the clinic, our aim is to investigate the potential and limitations of currently developed mAb‐based agents in improving cancer immunotherapy. With a narrative review of previous studies, it is hoped that these BsAbs, ICIs, and ADCs can be used as an efficient drug to target and treat human cancer while alleviating dangerous side effects in vivo.
AbstractList Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy. Immune checkpoints are antibodies targeting PD‐1, PD‐L1, and CTLA4 and have demonstrated remarkable therapeutic efficacy in the treatment of hematological and solid tumors, whose combination therapies have been shown to synergistically enhance the antitumor effects of BsAbs. In addition, the clinical efficacy of existing monoclonal antibodies targeting PD‐1 (e.g., ipilimumab, nivolumab, pembrolizumab, and cemiplimab) and PD‐L1 (e.g., atezolizumab, avelumab, and durvalumab) could also be enhanced by conjugation to small drugs as antibody−drug conjugates (ADCs). The development of truly effective therapies for patients with treatment‐resistant cancers can be achieved by optimizing the various components of ADCs. As the role of engineered antibodies in the development of various immunotherapeutic agents is now well established in the clinic, our aim is to investigate the potential and limitations of currently developed mAb‐based agents in improving cancer immunotherapy. With a narrative review of previous studies, it is hoped that these BsAbs, ICIs, and ADCs can be used as an efficient drug to target and treat human cancer while alleviating dangerous side effects in vivo.
Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy. Immune checkpoints are antibodies targeting PD-1, PD-L1, and CTLA4 and have demonstrated remarkable therapeutic efficacy in the treatment of hematological and solid tumors, whose combination therapies have been shown to synergistically enhance the antitumor effects of BsAbs. In addition, the clinical efficacy of existing monoclonal antibodies targeting PD-1 (e.g., ipilimumab, nivolumab, pembrolizumab, and cemiplimab) and PD-L1 (e.g., atezolizumab, avelumab, and durvalumab) could also be enhanced by conjugation to small drugs as antibody-drug conjugates (ADCs). The development of truly effective therapies for patients with treatment-resistant cancers can be achieved by optimizing the various components of ADCs.
Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy. Immune checkpoints are antibodies targeting PD-1, PD-L1, and CTLA4 and have demonstrated remarkable therapeutic efficacy in the treatment of hematological and solid tumors, whose combination therapies have been shown to synergistically enhance the antitumor effects of BsAbs. In addition, the clinical efficacy of existing monoclonal antibodies targeting PD-1 (e.g., ipilimumab, nivolumab, pembrolizumab, and cemiplimab) and PD-L1 (e.g., atezolizumab, avelumab, and durvalumab) could also be enhanced by conjugation to small drugs as antibody-drug conjugates (ADCs). The development of truly effective therapies for patients with treatment-resistant cancers can be achieved by optimizing the various components of ADCs.Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy. Immune checkpoints are antibodies targeting PD-1, PD-L1, and CTLA4 and have demonstrated remarkable therapeutic efficacy in the treatment of hematological and solid tumors, whose combination therapies have been shown to synergistically enhance the antitumor effects of BsAbs. In addition, the clinical efficacy of existing monoclonal antibodies targeting PD-1 (e.g., ipilimumab, nivolumab, pembrolizumab, and cemiplimab) and PD-L1 (e.g., atezolizumab, avelumab, and durvalumab) could also be enhanced by conjugation to small drugs as antibody-drug conjugates (ADCs). The development of truly effective therapies for patients with treatment-resistant cancers can be achieved by optimizing the various components of ADCs.
Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy. Immune checkpoints are antibodies targeting PD‐1, PD‐L1, and CTLA4 and have demonstrated remarkable therapeutic efficacy in the treatment of hematological and solid tumors, whose combination therapies have been shown to synergistically enhance the antitumor effects of BsAbs. In addition, the clinical efficacy of existing monoclonal antibodies targeting PD‐1 (e.g., ipilimumab, nivolumab, pembrolizumab, and cemiplimab) and PD‐L1 (e.g., atezolizumab, avelumab, and durvalumab) could also be enhanced by conjugation to small drugs as antibody−drug conjugates (ADCs). The development of truly effective therapies for patients with treatment‐resistant cancers can be achieved by optimizing the various components of ADCs.
ABSTRACT Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the family of antibodies that can specifically target two or more different antigens and are a promising option for tumor immunotherapy. Immune checkpoints are antibodies targeting PD‐1, PD‐L1, and CTLA4 and have demonstrated remarkable therapeutic efficacy in the treatment of hematological and solid tumors, whose combination therapies have been shown to synergistically enhance the antitumor effects of BsAbs. In addition, the clinical efficacy of existing monoclonal antibodies targeting PD‐1 (e.g., ipilimumab, nivolumab, pembrolizumab, and cemiplimab) and PD‐L1 (e.g., atezolizumab, avelumab, and durvalumab) could also be enhanced by conjugation to small drugs as antibody−drug conjugates (ADCs). The development of truly effective therapies for patients with treatment‐resistant cancers can be achieved by optimizing the various components of ADCs. Summary As the role of engineered antibodies in the development of various immunotherapeutic agents is now well established in the clinic, our aim is to investigate the potential and limitations of currently developed mAb‐based agents in improving cancer immunotherapy. With a narrative review of previous studies, it is hoped that these BsAbs, ICIs, and ADCs can be used as an efficient drug to target and treat human cancer while alleviating dangerous side effects in vivo.
Author Li, Chen Lu
Yi, Ping
Ma, Xin Yuan
Author_xml – sequence: 1
  givenname: Chen Lu
  orcidid: 0009-0002-3037-1956
  surname: Li
  fullname: Li, Chen Lu
  organization: Huazhong University of Science and Technology
– sequence: 2
  givenname: Xin Yuan
  surname: Ma
  fullname: Ma, Xin Yuan
  organization: Huazhong University of Science and Technology
– sequence: 3
  givenname: Ping
  surname: Yi
  fullname: Yi, Ping
  email: pyi219@163.com
  organization: Huazhong University of Science and Technology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39463028$$D View this record in MEDLINE/PubMed
BookMark eNp1kctuEzEUhi1URNPAghdAI7EBibS-ZcbDrp1SiFQJhGBteTzHqcOMPdgeobwB6z4iT4LTJJsKVrbk7_98LmfoxHkHCL0k-JxgTC90a84rjAl5gmYE1_UCC85P0AzTki1KLvgpOotxgzGuS4afoVNW83yhYobur2wcQVtjdXHpkm19ZyG-K1bDMDkomjvQP0ZvXSpW7s62NvmQX5XrjvT2z-_76zCti8a7zbRWCWJxbQPoZN36AUrT4MNR-BXi6F2E-D67Vd-DW-fAzvcl-F0lKT5HT43qI7w4nHP0_ebDt-bT4vbzx1VzebvQTAiS-6JcmWXJGOn0UlChWtBYcSBiyWndGmJYSSsNVHUG6qprM8JqaHPCgFJsjt7svWPwPyeISQ42auh75cBPUTJCCRW4yl_M0etH6MZPweXqMsVrQjCpeKZeHaipHaCTY7CDClt5nHYGLvaAzr3GAEZqm1Sy3qWgbC8Jlrt9yrxP-bDPnHj7KHGU_os92H_ZHrb_B2VzdbNP_AWP37Ep
CitedBy_id crossref_primary_10_20517_cdr_2024_180
crossref_primary_10_3390_cancers17020282
Cites_doi 10.1056/NEJMoa1209124
10.1182/blood-2020-136985
10.1158/0008-5472.CAN-20-1818
10.1007/s00262-015-1771-8
10.1016/S0140-6736(21)00889-8
10.3390/antib9020017
10.1186/s12935-021-02407-8
10.1016/j.jconrel.2023.05.032
10.2217/fon-2022-0844
10.1158/1078-0432.CCR-06-2854
10.1038/s41591-023-02726-5
10.1038/s41375-018-0210-1
10.3390/ph14030200
10.1016/j.jtho.2021.01.1161
10.1186/s40425-018-0420-0
10.1200/jco.2013.31.15_suppl.3061
10.1200/JCO.2017.35.15_suppl.2522
10.1186/s12943-024-01963-7
10.1007/s00432-020-03404-6
10.1186/s12935-021-02182-6
10.1038/s41388-018-0581-9
10.1016/S1470-2045(22)00621-0
10.1038/s41392-021-00868-x
10.1080/2162402X.2019.1644109
10.3389/fimmu.2023.1226360
10.3389/fimmu.2023.1227572
10.1007/s40267-022-00939-1
10.1002/cam4.1143
10.1007/s11523-021-00809-2
10.2217/imt-2020-0256
10.1016/S0140-6736(17)31266-7
10.1016/j.clcc.2016.07.009
10.1186/s12964-022-00854-y
10.1016/j.ccell.2020.08.007
10.1158/2326-6066.CIR-21-0515
10.1016/j.ekir.2020.10.002
10.1056/NEJMoa2203478
10.1016/S0140-6736(18)30207-1
10.1200/JCO.2017.76.6212
10.1158/1535-7163.MCT-15-0647
10.3390/vaccines5040038
10.1126/science.aan6733
10.1016/j.phrs.2024.107160
10.1093/neuonc/nop027
10.3390/ijms22115990
10.1080/2162402X.2022.2120676
10.1158/1538-7445.AM2021-1005
10.1159/000514420
10.1038/s41573-023-00709-2
10.1182/blood-2020-141250
10.3390/vaccines9070724
10.1158/0008-5472.CAN-11-1620
10.1182/blood.2019004701
10.1080/2162402X.2019.1657375
10.3389/fimmu.2021.626616
10.1007/s00262-011-1193-1
10.1080/21645515.2019.1631136
10.1093/neuonc/noaa260
10.1016/S1470-2045(21)00139-X
10.1038/s41571-021-00470-8
10.1038/s41557-024-01507-y
10.1053/j.gastro.2017.11.009
10.1016/j.ijrobp.2020.09.041
10.1182/blood-2020-136980
10.1016/S1470-2045(22)00128-0
10.1155/2021/8223263
10.1080/19420862.2024.2315640
10.1016/S0090-8258(22)01293-8
10.1016/j.xphs.2024.04.024
10.1056/NEJMoa1604958
10.2217/imt-2018-0009
10.1080/19420862.2016.1267090
10.3390/ijms25042097
10.1001/jamaoncol.2019.3343
10.1200/JCO.19.03296
10.1016/j.clbc.2024.03.004
10.1038/s41591-021-01233-9
10.1097/MEG.0000000000001956
10.1080/19420862.2024.2310890
10.3389/fimmu.2020.01792
10.1158/1078-0432.CCR-20-3770
10.1038/nrd.2016.268
10.1182/blood-2017-11-764332
10.1016/j.annonc.2020.10.552
10.1038/s41591-019-0382-x
10.1007/s12272-023-01433-6
10.1001/jamanetworkopen.2021.8065
10.3389/fmolb.2021.716735
10.1007/s11060-020-03459-y
10.1182/blood-2021-146868
10.1080/14728222.2021.1937123
10.1016/j.jtho.2020.03.003
10.1158/1535-7163.MCT-17-0657
10.1038/s41467-017-01062-w
10.1080/14712598.2022.2040987
10.1016/j.tibtech.2017.04.007
10.1016/j.intimp.2020.106939
10.1158/0008-5472.CAN-18-0892
10.1002/ajh.26809
10.1016/j.pep.2020.105635
10.1038/s41467-022-31457-3
10.1136/jclinpath-2019-206117
10.1038/s41591-018-0337-7
10.1056/NEJMoa1814213
10.1038/s41598-017-02503-8
10.2217/fon-2017-0646
10.1007/s00262-020-02493-z
10.1056/NEJMoa1509277
10.1016/j.ejmech.2019.111682
10.1016/j.lungcan.2022.03.005
10.1136/jitc-2020-001395
10.1093/annonc/mdt107
10.1056/NEJMoa1709684
ContentType Journal Article
Copyright 2024 John Wiley & Sons Ltd.
Copyright_xml – notice: 2024 John Wiley & Sons Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
7TM
7U7
8FD
C1K
FR3
P64
RC3
7X8
DOI 10.1002/cbf.70011
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Technology Research Database
Toxicology Abstracts
Nucleic Acids Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
MEDLINE - Academic
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Biology
EISSN 1099-0844
EndPage n/a
ExternalDocumentID 39463028
10_1002_cbf_70011
CBF70011
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: This study was supported by National Natural Science Foundation of China (NO.82174457).
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
29B
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AIACR
AIAGR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BLYAC
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LH6
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NDZJH
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V2E
V8K
W8V
W99
WBKPD
WH7
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WXI
WXSBR
WYISQ
XG1
XPP
XV2
ZZTAW
~IA
~WT
AAHHS
AAYXX
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
7TM
7U7
8FD
C1K
FR3
P64
RC3
7X8
ID FETCH-LOGICAL-c3881-6424af56331dc5828abec0a4e185429bf1f3627ce2adfe97db28a39eb633feaa3
IEDL.DBID DR2
ISSN 0263-6484
1099-0844
IngestDate Fri Jul 11 06:07:41 EDT 2025
Fri Jul 25 12:03:26 EDT 2025
Thu Apr 03 07:07:03 EDT 2025
Tue Jul 01 02:49:18 EDT 2025
Thu Apr 24 23:04:38 EDT 2025
Wed Aug 20 07:24:11 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords antibody−drug conjugates
immune checkpoint inhibitors
bispecific antibodies
monoclonal antibodies
tumor heterogeneity
Language English
License 2024 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3881-6424af56331dc5828abec0a4e185429bf1f3627ce2adfe97db28a39eb633feaa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0009-0002-3037-1956
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cbf.70011
PMID 39463028
PQID 3149110174
PQPubID 2029981
PageCount 14
ParticipantIDs proquest_miscellaneous_3121280756
proquest_journals_3149110174
pubmed_primary_39463028
crossref_citationtrail_10_1002_cbf_70011
crossref_primary_10_1002_cbf_70011
wiley_primary_10_1002_cbf_70011_CBF70011
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2024
2024-12-00
2024-Dec
20241201
PublicationDateYYYYMMDD 2024-12-01
PublicationDate_xml – month: 12
  year: 2024
  text: December 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Bognor Regis
PublicationTitle Cell biochemistry and function
PublicationTitleAlternate Cell Biochem Funct
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2010; 12
2019; 10
2022; 23
2020; 16
2017; 390
2024; 30
2020; 15
2022; 20
2020; 11
2022; 22
2020; 10
2012; 367
2022; 166
2018; 6
2021; 398
2020; 172
2019; 25
2021; 391
2022; 34
2024; 23
2020; 88
2024; 113
2024; 24
2024; 25
2018; 32
2022; 38
2022; 168
2021; 81
2021; 2021
2018; 36
2019; 8
2019; 5
2020; 38
2019; 38
2020; 146
2020; 147
2024; 16
2017; 377
2016; 15
2019; 183
2007; 13
2018; 17
2023; 46
2020; 31
2022; 7
2021; 138
2022; 13
2022; 10
2022; 1
2022; 11
2018; 10
2022; 18
2018; 14
2021; 25
2012; 61
2017; 5
2017; 6
2021; 27
2017; 7
2017; 8
2021; 21
2021; 23
2021; 22
2013; 24
2017; 9
2017; 357
2012; 72
2020; 8
2018; 131
2023; 22
2017; 35
2020; 9
2020; 136
2018; 78
2021; 9
2023; 98
2021; 8
2021; 109
2021; 6
2023; 14
2021; 4
2024; 203
2011; 34
2019; 380
2021; 14
2022; 387
2021; 13
2021; 16
2018; 154
2021; 12
2001; 7
2020; 73
2017; 16
2021; 18
2023; 359
2016; 65
2019
2016; 375
2020; 69
2013
e_1_2_13_24_1
e_1_2_13_47_1
e_1_2_13_20_1
e_1_2_13_66_1
e_1_2_13_101_1
e_1_2_13_43_1
e_1_2_13_85_1
e_1_2_13_8_1
e_1_2_13_62_1
e_1_2_13_92_1
e_1_2_13_96_1
e_1_2_13_117_1
e_1_2_13_17_1
e_1_2_13_13_1
e_1_2_13_36_1
e_1_2_13_59_1
e_1_2_13_32_1
e_1_2_13_55_1
e_1_2_13_78_1
e_1_2_13_112_1
e_1_2_13_51_1
e_1_2_13_74_1
Datta M. (e_1_2_13_7_1) 2019
e_1_2_13_70_1
e_1_2_13_4_1
e_1_2_13_105_1
e_1_2_13_88_1
e_1_2_13_29_1
e_1_2_13_109_1
e_1_2_13_25_1
e_1_2_13_48_1
e_1_2_13_100_1
e_1_2_13_21_1
e_1_2_13_44_1
e_1_2_13_67_1
e_1_2_13_104_1
e_1_2_13_86_1
e_1_2_13_9_1
e_1_2_13_40_1
e_1_2_13_63_1
e_1_2_13_82_1
e_1_2_13_91_1
Ströhlein M. A. (e_1_2_13_35_1) 2011; 34
e_1_2_13_95_1
e_1_2_13_116_1
e_1_2_13_99_1
e_1_2_13_18_1
e_1_2_13_14_1
e_1_2_13_111_1
e_1_2_13_37_1
e_1_2_13_79_1
e_1_2_13_10_1
e_1_2_13_56_1
e_1_2_13_115_1
e_1_2_13_33_1
e_1_2_13_75_1
e_1_2_13_52_1
e_1_2_13_71_1
e_1_2_13_5_1
e_1_2_13_108_1
e_1_2_13_49_1
e_1_2_13_68_1
e_1_2_13_45_1
e_1_2_13_87_1
e_1_2_13_22_1
e_1_2_13_64_1
e_1_2_13_103_1
e_1_2_13_41_1
e_1_2_13_60_1
e_1_2_13_83_1
e_1_2_13_6_1
e_1_2_13_90_1
Zhou C. (e_1_2_13_26_1) 2022; 1
e_1_2_13_94_1
e_1_2_13_98_1
e_1_2_13_119_1
e_1_2_13_19_1
e_1_2_13_15_1
e_1_2_13_38_1
e_1_2_13_57_1
e_1_2_13_110_1
e_1_2_13_11_1
e_1_2_13_34_1
e_1_2_13_53_1
e_1_2_13_76_1
e_1_2_13_114_1
e_1_2_13_30_1
e_1_2_13_72_1
Bross P. F. (e_1_2_13_107_1) 2001; 7
e_1_2_13_2_1
e_1_2_13_27_1
e_1_2_13_46_1
e_1_2_13_69_1
e_1_2_13_102_1
e_1_2_13_23_1
e_1_2_13_42_1
e_1_2_13_65_1
e_1_2_13_84_1
e_1_2_13_61_1
e_1_2_13_80_1
e_1_2_13_93_1
e_1_2_13_97_1
e_1_2_13_118_1
e_1_2_13_39_1
e_1_2_13_16_1
e_1_2_13_58_1
e_1_2_13_113_1
e_1_2_13_31_1
e_1_2_13_77_1
e_1_2_13_12_1
e_1_2_13_54_1
e_1_2_13_73_1
e_1_2_13_50_1
e_1_2_13_3_1
e_1_2_13_106_1
Fu D. (e_1_2_13_81_1) 2020; 10
e_1_2_13_89_1
e_1_2_13_28_1
References_xml – volume: 38
  start-page: 2053
  issue: 18
  year: 2020
  end-page: 2061
  article-title: Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open‐Label, Dose‐Escalation, and Dose‐Expansion Phase Ib Trial (REGONIVO, EPOC1603)
  publication-title: Journal of Clinical Oncology
– volume: 7
  start-page: 1490
  issue: 6
  year: 2001
  end-page: 1496
  article-title: Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia
  publication-title: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
– volume: 16
  start-page: 854
  year: 2024
  end-page: 870
  article-title: Homogeneous Multi‐Payload Antibody–Drug Conjugates
  publication-title: Nature Chemistry
– volume: 24
  start-page: 1813
  issue: 7
  year: 2013
  end-page: 1821
  article-title: Ipilimumab Alone or in Combination With Radiotherapy in Metastatic Castration‐Resistant Prostate Cancer: Results From an Open‐Label, Multicenter Phase I/II Study
  publication-title: Annals of Oncology
– volume: 390
  start-page: 555
  issue: 10094
  year: 2017
  end-page: 566
  article-title: Brentuximab Vedotin or Physician's Choice in CD30‐Positive Cutaneous T‐Cell Lymphoma (ALCANZA): An International, Open‐Label, Randomised, Phase 3, Multicentre Trial
  publication-title: Lancet
– volume: 9
  start-page: 724
  issue: 7
  year: 2021
  article-title: Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
  publication-title: Vaccines
– volume: 12
  start-page: 233
  issue: 3
  year: 2010
  end-page: 242
  article-title: Tumor Invasion After Treatment of Glioblastoma With Bevacizumab: Radiographic and Pathologic Correlation in Humans and Mice
  publication-title: Neuro‐oncology
– volume: 6
  start-page: 66
  issue: 1
  year: 2021
  end-page: 77
  article-title: A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease
  publication-title: Kidney International Reports
– volume: 377
  start-page: 1345
  issue: 14
  year: 2017
  end-page: 1356
  article-title: Overall Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma
  publication-title: New England Journal of Medicine
– volume: 146
  start-page: 3111
  year: 2020
  end-page: 3122
  article-title: Bispecific Antibodies Targeting Dual Tumor‐Associated Antigens in Cancer Therapy
  publication-title: Journal of Cancer Research and Clinical Oncology
– volume: 166
  start-page: S47
  year: 2022
  end-page: S48
  article-title: Efficacy and Safety of Cadonilimab, an Anti‐PD‐1/CTLA4 Bi‐Specific Antibody, in Previously Treated Recurrent or Metastatic (R/M) Cervical Cancer: A Multicenter, Open‐Label, Single‐Arm, Phase II Trial (075)
  publication-title: Gynecologic Oncology
– volume: 172
  year: 2020
  article-title: Removing Half Antibody Byproduct by Protein A Chromatography During the Purification of a Bispecific Antibody
  publication-title: Protein expression and purification
– volume: 136
  start-page: 42
  issue: S1
  year: 2020
  end-page: 43
  article-title: Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T‐Cell‐Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
  publication-title: Blood
– volume: 25
  start-page: 389
  issue: 3
  year: 2019
  end-page: 402
  article-title: Genomic Correlates of Response to Immune Checkpoint Blockade
  publication-title: Nature Medicine
– volume: 8
  issue: 2
  year: 2020
  article-title: Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1, in Patients With Human Papillomavirus‐Associated Malignancies
  publication-title: Journal for Immunotherapy of Cancer
– volume: 5
  start-page: 1731
  issue: 12
  year: 2019
  end-page: 1738
  article-title: Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
  publication-title: JAMA Oncology
– volume: 367
  start-page: 1783
  issue: 19
  year: 2012
  end-page: 1791
  article-title: Trastuzumab Emtansine for HER2‐Positive Advanced Breast Cancer
  publication-title: New England Journal of Medicine
– volume: 27
  start-page: 5457
  issue: 20
  year: 2021
  end-page: 5464
  article-title: Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
  publication-title: Clinical Cancer Research
– volume: 35
  start-page: 691
  issue: 8
  year: 2017
  end-page: 712
  article-title: Affibody Molecules in Biotechnological and Medical Applications
  publication-title: Trends in Biotechnology
– volume: 147
  start-page: 547
  year: 2020
  end-page: 555
  article-title: Repolarized Macrophages, Induced by Intermediate Stereotactic Dose Radiotherapy and Immune Checkpoint Blockade, Contribute to Long‐Term Survival in Glioma‐Bearing Mice
  publication-title: Journal of Neuro‐Oncology
– volume: 98
  start-page: 449
  issue: 3
  year: 2023
  end-page: 463
  article-title: Targeting MCL‐1 and BCL‐2 With Polatuzumab Vedotin and Venetoclax Overcomes Treatment Resistance in R/R Non‐Hodgkin Lymphoma: Results From Preclinical Models and a Phase Ib Study
  publication-title: American Journal of Hematology
– volume: 7
  start-page: 2396
  issue: 1
  year: 2017
  article-title: Cooperation of Oncolytic Herpes Virotherapy and PD‐1 Blockade in Murine Rhabdomyosarcoma Models
  publication-title: Scientific Reports
– volume: 38
  start-page: 2380
  issue: 13
  year: 2019
  end-page: 2393
  article-title: Cisplatin‐Induced Immune Modulation in Ovarian Cancer Mouse Models With Distinct Inflammation Profiles
  publication-title: Oncogene
– volume: 32
  start-page: 1768
  issue: 8
  year: 2018
  end-page: 1777
  article-title: Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
  publication-title: Leukemia
– volume: 25
  start-page: 477
  issue: 3
  year: 2019
  end-page: 486
  article-title: Neoadjuvant Anti‐PD‐1 Immunotherapy Promotes a Survival Benefit With Intratumoral and Systemic Immune Responses in Recurrent Glioblastoma
  publication-title: Nature Medicine
– volume: 359
  start-page: 268
  year: 2023
  end-page: 286
  article-title: Bispecific Antibodies for Targeted Delivery of Anti‐Cancer Therapeutic Agents: A Review
  publication-title: Journal of Controlled Release
– volume: 22
  start-page: 641
  issue: 8
  year: 2023
  end-page: 661
  article-title: Antibody–Drug Conjugates Come of Age in Oncology
  publication-title: Nature Reviews Drug Discovery
– volume: 38
  start-page: 382
  issue: 9
  year: 2022
  end-page: 388
  article-title: Tisotumab Vedotin‐Tftv in Previously Treated Recurrent or Metastatic Cervical Cancer: a Profile of Its Use in the USA
  publication-title: Drugs & Therapy Perspectives
– year: 2019
– volume: 25
  start-page: 2097
  issue: 4
  year: 2024
  article-title: A Generic Approach for Miniaturized Unbiased High‐Throughput Screens of Bispecific Antibodies and Biparatopic Antibody–Drug Conjugates
  publication-title: International Journal of Molecular Sciences
– volume: 78
  start-page: 5327
  issue: 18
  year: 2018
  end-page: 5339
  article-title: Mucosal HPV E6/E7 Peptide Vaccination in Combination With Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers
  publication-title: Cancer Research
– volume: 8
  year: 2021
  article-title: Discovery of Novel Inhibitors From Medicinal Plants for v‐Domain ig Suppressor of T‐Cell Activation
  publication-title: Frontiers in Molecular Biosciences
– volume: 81
  start-page: 685
  issue: 3
  year: 2021
  end-page: 697
  article-title: Cyclophosphamide and Vinorelbine Activate Stem‐Like CD8+ T Cells and Improve Anti‐PD‐1 Efficacy in Triple‐Negative Breast Cancer
  publication-title: Cancer Research
– volume: 22
  start-page: 945
  issue: 8
  year: 2022
  end-page: 949
  article-title: The Evolution of Bispecific Antibodies
  publication-title: Expert Opinion on Biological Therapy
– volume: 34
  start-page: 101
  issue: 3
  year: 2011
  end-page: 108
  article-title: Immunotherapy of Peritoneal Carcinomatosis With the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open‐Label, Multicenter, Phase I/II Trial
  publication-title: Oncology Research and Treatment
– volume: 14
  start-page: 200
  issue: 3
  year: 2021
  article-title: TIGIT/CD226 Axis Regulates Anti‐Tumor Immunity
  publication-title: Pharmaceuticals
– volume: 11
  issue: 1
  year: 2022
  article-title: Immunosuppressive Tumor Microenvironment Modulation by Chemotherapies and Targeted Therapies to Enhance Immunotherapy Effectiveness
  publication-title: Oncoimmunology
– volume: 11
  year: 2020
  article-title: Engineering Immune Cells for In Vivo Secretion of Tumor‐Specific T Cell‐Redirecting Bispecific Antibodies
  publication-title: Frontiers in Immunology
– volume: 13
  start-page: 125
  issue: 2
  year: 2021
  end-page: 141
  article-title: Pasotuxizumab, a BiTE Immune Therapy for Castration‐Resistant Prostate Cancer: Phase I, Dose‐Escalation Study Findings
  publication-title: Immunotherapy
– volume: 375
  start-page: 740
  issue: 8
  year: 2016
  end-page: 753
  article-title: Inotuzumab Ozogamicin Versus Standard Therapy for Acute Lymphoblastic Leukemia
  publication-title: New England Journal of Medicine
– volume: 20
  start-page: 44
  issue: 1
  year: 2022
  article-title: Tumor Immunotherapies by Immune Checkpoint Inhibitors (ICIs); The Pros and Cons
  publication-title: Cell Communication and Signaling
– volume: 16
  start-page: 112
  issue: 1
  year: 2020
  end-page: 115
  article-title: Tumor Mutational Burden as a Predictive Biomarker for Checkpoint Inhibitor Immunotherapy
  publication-title: Human Vaccines & Immunotherapeutics
– volume: 38
  start-page: 489
  issue: 4
  year: 2020
  end-page: 499.e3
  article-title: Nivolumab Plus Ipilimumab for Metastatic Castration‐Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
  publication-title: Cancer Cell
– volume: 136
  start-page: 14
  year: 2020
  end-page: 15
  article-title: Early Pharmacodynamic Changes in T‐Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T‐Cell‐Engaging Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
  publication-title: Blood
– volume: 88
  year: 2020
  article-title: Effects of Immune Cells and Cytokines on Inflammation and Immunosuppression in the Tumor Microenvironment
  publication-title: International Immunopharmacology
– year: 2013
  article-title: Antitumor Activity of Concurrent Blockade of Immune Checkpoint Molecules CTLA‐4 and PD‐1 in Preclinical Models
  publication-title: American Society of Clinical Oncology
– volume: 4
  issue: 5
  year: 2021
  article-title: Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum‐Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta‐Analysis and Cost‐Effectiveness Analysis
  publication-title: JAMA Network Open
– volume: 16
  issue: 1
  year: 2024
  article-title: Biparatopic Antibodies: Therapeutic Applications and Prospects
  publication-title: Mabs
– volume: 375
  start-page: 819
  issue: 9
  year: 2016
  end-page: 829
  article-title: Mutations Associated With Acquired Resistance to PD‐1 Blockade in Melanoma
  publication-title: New England Journal of Medicine
– volume: 8
  start-page: 1136
  issue: 1
  year: 2017
  article-title: Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation
  publication-title: Nature Communications
– volume: 387
  start-page: 495
  issue: 6
  year: 2022
  end-page: 505
  article-title: Teclistamab in Relapsed or Refractory Multiple Myeloma
  publication-title: New England Journal of Medicine
– volume: 136
  start-page: 2401
  issue: 21
  year: 2020
  end-page: 2409
  article-title: A Phase 1b Study of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
  publication-title: Blood
– volume: 391
  start-page: 1163
  issue: 10126
  year: 2021
  end-page: 1173
  article-title: Lenvatinib Versus Sorafenib in First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial
  publication-title: Lancet
– volume: 6
  start-page: 109
  year: 2018
  article-title: Safety and Efficacy of Nivolumab in Combination With Sunitinib or Pazopanib in Advanced or Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
  publication-title: Journal for Immunotherapy of Cancer
– volume: 36
  start-page: 2836
  issue: 28
  year: 2018
  end-page: 2844
  article-title: CheckMate‐032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
  publication-title: Journal of Clinical Oncology
– volume: 2021
  start-page: 1
  year: 2021
  end-page: 10
  article-title: Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non‐Small‐Cell Lung Cancer and Prostate Cancer: A Meta‐Analysis
  publication-title: Journal of Oncology
– volume: 18
  start-page: 4465
  issue: 40
  year: 2022
  end-page: 4471
  article-title: A Multicenter, Phase Ib/II, Open‐Label Study of Tivozanib With Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)
  publication-title: Future oncology
– volume: 14
  year: 2023
  article-title: Immunotherapies Targeting Tumor Vasculature: Challenges and Opportunities
  publication-title: Frontiers in Immunology
– volume: 23
  start-page: 62
  issue: 1
  year: 2024
  article-title: A Review of the Clinical Efficacy of FDA‐Approved Antibody‒Drug Conjugates in Human Cancers
  publication-title: Molecular Cancer
– volume: 16
  issue: 3
  year: 2021
  article-title: P77. 03 a Phase II Study of KN046 (Bispecific Anti‐PD‐L1/CTLA‐4) in Patients (PTS) With Metastatic Non‐Small Cell Lung Cancer (NSCLC)
  publication-title: Journal of Thoracic Oncology
– volume: 7
  start-page: 39
  issue: 1
  year: 2022
  article-title: Emerging New Therapeutic Antibody Derivatives for Cancer Treatment
  publication-title: Signal Transduction and Targeted Therapy
– volume: 16
  start-page: 315
  issue: 5
  year: 2017
  end-page: 337
  article-title: Strategies and Challenges for the Next Generation of Antibody–Drug Conjugates
  publication-title: Nature Reviews Drug Discovery
– volume: 81
  start-page: 1005
  issue: S13
  year: 2021
  article-title: Abstract 1005: The Bispecific Antibody Zanidatamab's (ZW25's) Unique Mechanisms of Action and Durable Anti‐Tumor Activity in HER2‐Expressing Cancers
  publication-title: Cancer Research
– volume: 23
  start-page: 612
  issue: 5
  year: 2022
  end-page: 624
  article-title: Nivolumab, Nivolumab–Ipilimumab, and VEGFR‐Tyrosine Kinase Inhibitors as First‐Line Treatment for Metastatic Clear‐Cell Renal Cell Carcinoma (BIONIKK): A Biomarker‐Driven, Open‐Label, Non‐Comparative, Randomised, Phase 2 Trial
  publication-title: Lancet Oncology
– volume: 17
  start-page: 776
  issue: 4
  year: 2018
  end-page: 785
  article-title: Relative Target Affinities of T‐Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
  publication-title: Molecular Cancer Therapeutics
– volume: 131
  start-page: 2307
  issue: 21
  year: 2018
  end-page: 2319
  article-title: Genetics of Diffuse Large B‐Cell Lymphoma
  publication-title: Blood
– volume: 24
  start-page: 328
  year: 2024
  end-page: 336
  article-title: Systemic Therapy Advances for HER2‐Positive and Triple Negative Breast Cancer–What the Surgeon Needs to Know
  publication-title: Clinical Breast Cancer
– volume: 22
  start-page: 790
  issue: 6
  year: 2021
  end-page: 800
  article-title: Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B‐Cell Lymphoma (LOTIS‐2): A Multicentre, Open‐Label, Single‐Arm, Phase 2 Trial
  publication-title: Lancet Oncology
– volume: 69
  start-page: 641
  year: 2020
  end-page: 651
  article-title: Bovine Papillomavirus Prostate Cancer Antigen Virus‐Like Particle Vaccines Are Efficacious in Advanced Cancers in the TRAMP Mouse Spontaneous Prostate Cancer Model
  publication-title: Cancer Immunology, Immunotherapy
– volume: 203
  year: 2024
  article-title: When Will the Immune‐Stimulating Antibody Conjugates (ISACs) be Transferred From Bench to Bedside
  publication-title: Pharmacological Research
– volume: 9
  start-page: 257
  issue: 2
  year: 2017
  end-page: 268
  article-title: Purification of Common Light Chain IgG‐Like Bispecific Antibodies Using Highly Linear pH Gradients
  publication-title: MAbs
– volume: 18
  start-page: 327
  issue: 6
  year: 2021
  end-page: 344
  article-title: Unlocking the Potential of Antibody–Drug Conjugates for Cancer Therapy
  publication-title: Nature Reviews Clinical Oncology
– volume: 357
  start-page: 409
  issue: 6349
  year: 2017
  end-page: 413
  article-title: Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD‐1 Blockade
  publication-title: Science
– volume: 15
  start-page: 946
  issue: 5
  year: 2016
  end-page: 957
  article-title: RG7386, a Novel Tetravalent FAP‐DR5 Antibody, Effectively Triggers FAP‐Dependent, Avidity‐Driven DR5 Hyperclustering and Tumor Cell Apoptosis
  publication-title: Molecular Cancer Therapeutics
– volume: 25
  start-page: 347
  issue: 5
  year: 2021
  end-page: 363
  article-title: Reversing T‐Cell Exhaustion in Immunotherapy: A Review on Current Approaches and Limitations
  publication-title: Expert Opinion on Therapeutic Targets
– volume: 5
  start-page: 38
  issue: 4
  year: 2017
  article-title: An Archaeosome‐Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection From Murine Melanoma
  publication-title: Vaccines
– volume: 73
  start-page: 197
  issue: 4
  year: 2020
  end-page: 203
  article-title: Expression of the Checkpoint Receptors LAG‐3, TIM‐3 and VISTA in Peripheral T Cell Lymphomas
  publication-title: Journal of Clinical Pathology
– volume: 65
  start-page: 779
  year: 2016
  end-page: 786
  article-title: Immune‐Modulating Properties of Ionizing Radiation: Rationale for the Treatment of Cancer by Combination Radiotherapy and Immune Checkpoint Inhibitors
  publication-title: Cancer Immunology, Immunotherapy
– volume: 34
  start-page: 213
  issue: 2
  year: 2022
  end-page: 219
  article-title: Combining Immune Checkpoint Inhibitor With Lenvatinib Prolongs Survival Than Lenvatinib Alone in Sorafenib‐Experienced Hepatocellular Carcinoma Patients
  publication-title: European Journal of Gastroenterology & Hepatology
– volume: 14
  start-page: 1669
  issue: 17
  year: 2018
  end-page: 1678
  article-title: FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum‐Resistant Ovarian Cancer
  publication-title: Future Oncology
– volume: 109
  start-page: 594
  issue: 2
  year: 2021
  end-page: 602
  article-title: Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors
  publication-title: International Journal of Radiation Oncology* Biology* Physics
– volume: 10
  start-page: 146
  issue: 2
  year: 2022
  end-page: 153
  article-title: Reversing T‐Cell Exhaustion in Cancer: Lessons Learned From PD‐1/PD‐L1 Immune Checkpoint Blockade
  publication-title: Cancer Immunology Research
– volume: 23
  start-page: 677
  issue: 4
  year: 2021
  end-page: 686
  article-title: Hypofractionated Stereotactic Re‐Irradiation With Pembrolizumab and Bevacizumab in Patients With Recurrent High‐Grade Gliomas: Results From a Phase I Study
  publication-title: Neuro‐oncology
– volume: 72
  start-page: 917
  issue: 4
  year: 2012
  end-page: 927
  article-title: Immune Inhibitory Molecules LAG‐3 and PD‐1 Synergistically Regulate T‐Cell Function to Promote Tumoral Immune Escape
  publication-title: Cancer Research
– volume: 27
  start-page: 212
  issue: 2
  year: 2021
  end-page: 224
  article-title: Intratumoral Heterogeneity in Cancer Progression and Response to Immunotherapy
  publication-title: Nature Medicine
– volume: 14
  year: 2023
  article-title: Novel NKG2D‐Directed Bispecific Antibodies Enhance Antibody‐Mediated Killing of Malignant B Cells by NK Cells and T Cells
  publication-title: Frontiers in Immunology
– volume: 23
  start-page: 1558
  issue: 12
  year: 2021
  end-page: 1570
  article-title: Zanidatamab, a Novel Bispecific Antibody, for the Treatment of Locally Advanced or Metastatic HER2‐Expressing or HER2‐Amplified Cancers: A Phase 1, Dose‐Escalation and Expansion Study
  publication-title: Lancet Oncology
– volume: 8
  issue: 11
  year: 2019
  article-title: A Synergistic Triad of Chemotherapy, Immune Checkpoint Inhibitors, and Caloric Restriction Mimetics Eradicates Tumors in Mice
  publication-title: Oncoimmunology
– volume: 13
  start-page: 3788
  issue: 1
  year: 2022
  article-title: Co‐Optimization of Therapeutic Antibody Affinity and Specificity Using Machine Learning Models That Generalize to Novel Mutational Space
  publication-title: Nature Communications
– volume: 46
  start-page: 131
  issue: 3
  year: 2023
  end-page: 148
  article-title: Antibody–Drug Conjugates and Bispecific Antibodies Targeting Cancers: Applications of Click Chemistry
  publication-title: Archives of Pharmacal Research
– volume: 12
  year: 2021
  article-title: Bispecific Antibodies: From Research to Clinical Application
  publication-title: Frontiers in Immunology
– volume: 22
  start-page: 5990
  issue: 11
  year: 2021
  article-title: Combined Gemcitabine and Immune‐Checkpoint Inhibition Conquers Anti‐PD‐L1 Resistance in Low‐Immunogenic Mismatch Repair‐Deficient Tumors
  publication-title: International Journal of Molecular Sciences
– volume: 10
  start-page: 473
  issue: 2
  year: 2020
  end-page: 490
  article-title: T Cell Recruitment Triggered by Optimal Dose Platinum Compounds Contributes to the Therapeutic Efficacy of Sequential PD‐1 Blockade in a Mouse Model of Colon Cancer
  publication-title: American Journal of Cancer Research
– volume: 22
  start-page: 2
  year: 2022
  article-title: Combination Therapy With Immune Checkpoint Inhibitors (ICIs); A New Frontier
  publication-title: Cancer Cell International
– volume: 168
  start-page: 74
  year: 2022
  end-page: 82
  article-title: Amivantamab Compared With Real‐World Therapies in Patients With Advanced Non‐Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Progressed After Platinum‐Based Chemotherapy
  publication-title: Lung Cancer
– volume: 61
  start-page: 1137
  year: 2012
  end-page: 1147
  article-title: Phase I Trial of Tremelimumab in Combination With Short‐Term Androgen Deprivation in Patients With PSA‐Recurrent Prostate Cancer
  publication-title: Cancer Immunology, Immunotherapy
– volume: 15
  start-page: 1210
  issue: 7
  year: 2020
  end-page: 1222
  article-title: Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1, in Second‐Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
  publication-title: Journal of Thoracic Oncology
– volume: 380
  start-page: 741
  issue: 8
  year: 2019
  end-page: 751
  article-title: Sacituzumab Govitecan‐Hziy in Refractory Metastatic Triple‐Negative Breast Cancer
  publication-title: New England Journal of Medicine
– volume: 16
  start-page: 435
  issue: 4
  year: 2021
  end-page: 446
  article-title: Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1, in Patients With Esophageal Adenocarcinoma: Results From a Phase 1 Cohort
  publication-title: Targeted Oncology
– volume: 8
  issue: 11
  year: 2019
  article-title: Immune Checkpoint Inhibitors in mCRPC‐Rationales, Challenges and Perspectives
  publication-title: Oncoimmunology
– volume: 30
  start-page: 229
  issue: 1
  year: 2024
  end-page: 239
  article-title: Mosunetuzumab With Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b/2 Trial
  publication-title: Nature Medicine
– volume: 35
  start-page: 2522
  issue: S15
  year: 2017
  article-title: First‐In‐Human Phase 1/2 Study of MCLA‐128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3: Final Phase 1 Data and Preliminary Activity in HER2+ Metastatic Breast Cancer (MBC)
  publication-title: Journal of Clinical Oncology
– volume: 10
  start-page: 249
  issue: 3
  year: 2019
  end-page: 259
  article-title: Avelumab in Combination With Axitinib as First‐Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
  publication-title: Liver cancer
– volume: 183
  year: 2019
  article-title: Novel HER2‐Targeting Antibody‐Drug Conjugates of Trastuzumab Beyond T‐DM1 in Breast Cancer: Trastuzumab Deruxtecan (DS‐8201a) and (Vic‐) Trastuzumab Duocarmazine (Syd985)
  publication-title: European Journal of Medicinal Chemistry
– volume: 113
  start-page: 2443
  year: 2024
  end-page: 2453
  article-title: Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody–Drug Conjugates With Different Payloads
  publication-title: Journal of Pharmaceutical Sciences
– volume: 9
  start-page: 17
  issue: 2
  year: 2020
  article-title: Combined Anti‐Cancer Strategies Based on Anti‐Checkpoint Inhibitor Antibodies
  publication-title: Antibodies
– volume: 6
  start-page: 2052
  issue: 9
  year: 2017
  end-page: 2062
  article-title: A Combination of Anti‐PD‐L1 mA b Plus Lm‐LLO‐E6 Vaccine Efficiently Suppresses Tumor Growth and Metastasis in HPV‐Infected Cancers
  publication-title: Cancer Medicine
– volume: 1
  start-page: 10
  year: 2022
  article-title: A Phase Ib/II Study of AK112, a PD‐1/VEGF Bispecific Antibody, as First or Second‐Line Therapy for Advanced Non‐Small Cell Lung Cancer (NSCLC)
  publication-title: Hypertension
– volume: 21
  start-page: 470
  year: 2021
  article-title: Recombinant Immunotoxins Development for HER2‐Based Targeted Cancer Therapies
  publication-title: Cancer Cell International
– volume: 398
  start-page: 1157
  issue: 10306
  year: 2021
  end-page: 1169
  article-title: Dose Escalation of Subcutaneous Epcoritamab in Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma: An Open‐Label, Phase 1/2 Study
  publication-title: Lancet
– volume: 138
  start-page: 158
  year: 2021
  article-title: Updated Phase 1 Results From MonumenTAL‐1: First‐In‐Human Study of Talquetamab, a G Protein‐Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
  publication-title: Blood
– volume: 31
  start-page: S1442
  year: 2020
  end-page: S1443
  article-title: 64MO A Phase (ph) II, Multi‐Center Study of the Safety and Efficacy of Tebentafusp (tebe)(IMCgp100) in Patients (pts) With Metastatic Uveal Melanoma (mUM)
  publication-title: Annals of Oncology
– volume: 15
  start-page: 345
  issue: 4
  year: 2016
  end-page: 351
  article-title: Phase 1 Dose Escalation Study of MEDI‐565, a Bispecific T‐Cell Engager That Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
  publication-title: Clinical Colorectal Cancer
– volume: 16
  issue: 1
  year: 2024
  article-title: Impact of Antibody Architecture and Paratope Valency on Effector Functions of Bispecific NKp30 x EGFR Natural Killer Cell Engagers
  publication-title: Mabs
– volume: 10
  start-page: 779
  issue: 9
  year: 2018
  end-page: 786
  article-title: Oncolytic Herpes Simplex Virus Immunovirotherapy in Combination With Immune Checkpoint Blockade to Treat Glioblastoma
  publication-title: Immunotherapy
– volume: 154
  start-page: 1061
  issue: 4
  year: 2018
  end-page: 1065
  article-title: Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas
  publication-title: Gastroenterology
– volume: 13
  start-page: 1663
  issue: 6
  year: 2007
  end-page: 1674
  article-title: The Blood‐Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
  publication-title: Clinical Cancer Research
– volume: 136
  start-page: 31
  year: 2020
  end-page: 32
  article-title: AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open‐Label, Randomized, Multicenter Phase II Trial
  publication-title: Blood
– ident: e_1_2_13_104_1
  doi: 10.1056/NEJMoa1209124
– ident: e_1_2_13_30_1
  doi: 10.1182/blood-2020-136985
– ident: e_1_2_13_78_1
  doi: 10.1158/0008-5472.CAN-20-1818
– ident: e_1_2_13_89_1
  doi: 10.1007/s00262-015-1771-8
– ident: e_1_2_13_28_1
  doi: 10.1016/S0140-6736(21)00889-8
– ident: e_1_2_13_11_1
  doi: 10.3390/antib9020017
– ident: e_1_2_13_51_1
  doi: 10.1186/s12935-021-02407-8
– ident: e_1_2_13_12_1
  doi: 10.1016/j.jconrel.2023.05.032
– ident: e_1_2_13_37_1
  doi: 10.2217/fon-2022-0844
– ident: e_1_2_13_74_1
  doi: 10.1158/1078-0432.CCR-06-2854
– ident: e_1_2_13_23_1
  doi: 10.1038/s41591-023-02726-5
– ident: e_1_2_13_108_1
  doi: 10.1038/s41375-018-0210-1
– ident: e_1_2_13_4_1
  doi: 10.3390/ph14030200
– ident: e_1_2_13_34_1
  doi: 10.1016/j.jtho.2021.01.1161
– ident: e_1_2_13_93_1
  doi: 10.1186/s40425-018-0420-0
– ident: e_1_2_13_2_1
  doi: 10.1200/jco.2013.31.15_suppl.3061
– ident: e_1_2_13_40_1
  doi: 10.1200/JCO.2017.35.15_suppl.2522
– volume: 7
  start-page: 1490
  issue: 6
  year: 2001
  ident: e_1_2_13_107_1
  article-title: Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia
  publication-title: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
– ident: e_1_2_13_14_1
  doi: 10.1186/s12943-024-01963-7
– ident: e_1_2_13_21_1
  doi: 10.1007/s00432-020-03404-6
– volume-title: Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies
  year: 2019
  ident: e_1_2_13_7_1
– ident: e_1_2_13_57_1
  doi: 10.1186/s12935-021-02182-6
– ident: e_1_2_13_79_1
  doi: 10.1038/s41388-018-0581-9
– ident: e_1_2_13_38_1
  doi: 10.1016/S1470-2045(22)00621-0
– volume: 10
  start-page: 473
  issue: 2
  year: 2020
  ident: e_1_2_13_81_1
  article-title: T Cell Recruitment Triggered by Optimal Dose Platinum Compounds Contributes to the Therapeutic Efficacy of Sequential PD‐1 Blockade in a Mouse Model of Colon Cancer
  publication-title: American Journal of Cancer Research
– ident: e_1_2_13_19_1
  doi: 10.1038/s41392-021-00868-x
– ident: e_1_2_13_72_1
  doi: 10.1080/2162402X.2019.1644109
– ident: e_1_2_13_77_1
  doi: 10.3389/fimmu.2023.1226360
– ident: e_1_2_13_18_1
  doi: 10.3389/fimmu.2023.1227572
– ident: e_1_2_13_113_1
  doi: 10.1007/s40267-022-00939-1
– ident: e_1_2_13_88_1
  doi: 10.1002/cam4.1143
– ident: e_1_2_13_99_1
  doi: 10.1007/s11523-021-00809-2
– ident: e_1_2_13_43_1
  doi: 10.2217/imt-2020-0256
– ident: e_1_2_13_105_1
  doi: 10.1016/S0140-6736(17)31266-7
– ident: e_1_2_13_36_1
  doi: 10.1016/j.clcc.2016.07.009
– ident: e_1_2_13_52_1
  doi: 10.1186/s12964-022-00854-y
– ident: e_1_2_13_60_1
  doi: 10.1016/j.ccell.2020.08.007
– ident: e_1_2_13_6_1
  doi: 10.1158/2326-6066.CIR-21-0515
– ident: e_1_2_13_69_1
  doi: 10.1016/j.ekir.2020.10.002
– ident: e_1_2_13_24_1
  doi: 10.1056/NEJMoa2203478
– ident: e_1_2_13_39_1
  doi: 10.1016/S0140-6736(18)30207-1
– ident: e_1_2_13_100_1
  doi: 10.1200/JCO.2017.76.6212
– ident: e_1_2_13_50_1
  doi: 10.1158/1535-7163.MCT-15-0647
– ident: e_1_2_13_86_1
  doi: 10.3390/vaccines5040038
– ident: e_1_2_13_70_1
  doi: 10.1126/science.aan6733
– ident: e_1_2_13_119_1
  doi: 10.1016/j.phrs.2024.107160
– ident: e_1_2_13_73_1
  doi: 10.1093/neuonc/nop027
– ident: e_1_2_13_80_1
  doi: 10.3390/ijms22115990
– ident: e_1_2_13_8_1
  doi: 10.1080/2162402X.2022.2120676
– ident: e_1_2_13_27_1
  doi: 10.1158/1538-7445.AM2021-1005
– ident: e_1_2_13_96_1
  doi: 10.1159/000514420
– ident: e_1_2_13_102_1
  doi: 10.1038/s41573-023-00709-2
– ident: e_1_2_13_29_1
  doi: 10.1182/blood-2020-141250
– ident: e_1_2_13_16_1
  doi: 10.3390/vaccines9070724
– ident: e_1_2_13_3_1
  doi: 10.1158/0008-5472.CAN-11-1620
– ident: e_1_2_13_98_1
  doi: 10.1182/blood.2019004701
– ident: e_1_2_13_82_1
  doi: 10.1080/2162402X.2019.1657375
– ident: e_1_2_13_10_1
  doi: 10.3389/fimmu.2021.626616
– ident: e_1_2_13_58_1
  doi: 10.1007/s00262-011-1193-1
– ident: e_1_2_13_68_1
  doi: 10.1080/21645515.2019.1631136
– ident: e_1_2_13_62_1
  doi: 10.1093/neuonc/noaa260
– ident: e_1_2_13_112_1
  doi: 10.1016/S1470-2045(21)00139-X
– ident: e_1_2_13_103_1
  doi: 10.1038/s41571-021-00470-8
– ident: e_1_2_13_115_1
  doi: 10.1038/s41557-024-01507-y
– ident: e_1_2_13_71_1
  doi: 10.1053/j.gastro.2017.11.009
– ident: e_1_2_13_91_1
  doi: 10.1016/j.ijrobp.2020.09.041
– ident: e_1_2_13_31_1
  doi: 10.1182/blood-2020-136980
– ident: e_1_2_13_55_1
  doi: 10.1016/S1470-2045(22)00128-0
– ident: e_1_2_13_92_1
  doi: 10.1155/2021/8223263
– ident: e_1_2_13_46_1
  doi: 10.1080/19420862.2024.2315640
– ident: e_1_2_13_41_1
  doi: 10.1016/S0090-8258(22)01293-8
– ident: e_1_2_13_116_1
  doi: 10.1016/j.xphs.2024.04.024
– ident: e_1_2_13_63_1
  doi: 10.1056/NEJMoa1604958
– ident: e_1_2_13_83_1
  doi: 10.2217/imt-2018-0009
– ident: e_1_2_13_15_1
  doi: 10.1080/19420862.2016.1267090
– ident: e_1_2_13_117_1
  doi: 10.3390/ijms25042097
– ident: e_1_2_13_97_1
  doi: 10.1001/jamaoncol.2019.3343
– ident: e_1_2_13_95_1
  doi: 10.1200/JCO.19.03296
– ident: e_1_2_13_56_1
  doi: 10.1016/j.clbc.2024.03.004
– ident: e_1_2_13_75_1
  doi: 10.1038/s41591-021-01233-9
– ident: e_1_2_13_94_1
  doi: 10.1097/MEG.0000000000001956
– ident: e_1_2_13_118_1
  doi: 10.1080/19420862.2024.2310890
– ident: e_1_2_13_17_1
  doi: 10.3389/fimmu.2020.01792
– ident: e_1_2_13_20_1
  doi: 10.1158/1078-0432.CCR-20-3770
– ident: e_1_2_13_101_1
  doi: 10.1038/nrd.2016.268
– ident: e_1_2_13_109_1
  doi: 10.1182/blood-2017-11-764332
– ident: e_1_2_13_44_1
  doi: 10.1016/j.annonc.2020.10.552
– ident: e_1_2_13_65_1
  doi: 10.1038/s41591-019-0382-x
– ident: e_1_2_13_13_1
  doi: 10.1007/s12272-023-01433-6
– ident: e_1_2_13_53_1
  doi: 10.1001/jamanetworkopen.2021.8065
– ident: e_1_2_13_67_1
  doi: 10.3389/fmolb.2021.716735
– ident: e_1_2_13_90_1
  doi: 10.1007/s11060-020-03459-y
– ident: e_1_2_13_32_1
  doi: 10.1182/blood-2021-146868
– ident: e_1_2_13_5_1
  doi: 10.1080/14728222.2021.1937123
– volume: 34
  start-page: 101
  issue: 3
  year: 2011
  ident: e_1_2_13_35_1
  article-title: Immunotherapy of Peritoneal Carcinomatosis With the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open‐Label, Multicenter, Phase I/II Trial
  publication-title: Oncology Research and Treatment
– ident: e_1_2_13_33_1
  doi: 10.1016/j.jtho.2020.03.003
– ident: e_1_2_13_45_1
  doi: 10.1158/1535-7163.MCT-17-0657
– ident: e_1_2_13_64_1
  doi: 10.1038/s41467-017-01062-w
– ident: e_1_2_13_9_1
  doi: 10.1080/14712598.2022.2040987
– ident: e_1_2_13_49_1
  doi: 10.1016/j.tibtech.2017.04.007
– ident: e_1_2_13_76_1
  doi: 10.1016/j.intimp.2020.106939
– ident: e_1_2_13_84_1
  doi: 10.1158/0008-5472.CAN-18-0892
– ident: e_1_2_13_22_1
  doi: 10.1002/ajh.26809
– ident: e_1_2_13_48_1
  doi: 10.1016/j.pep.2020.105635
– ident: e_1_2_13_47_1
  doi: 10.1038/s41467-022-31457-3
– ident: e_1_2_13_66_1
  doi: 10.1136/jclinpath-2019-206117
– ident: e_1_2_13_61_1
  doi: 10.1038/s41591-018-0337-7
– ident: e_1_2_13_110_1
  doi: 10.1056/NEJMoa1814213
– volume: 1
  start-page: 10
  year: 2022
  ident: e_1_2_13_26_1
  article-title: A Phase Ib/II Study of AK112, a PD‐1/VEGF Bispecific Antibody, as First or Second‐Line Therapy for Advanced Non‐Small Cell Lung Cancer (NSCLC)
  publication-title: Hypertension
– ident: e_1_2_13_87_1
  doi: 10.1038/s41598-017-02503-8
– ident: e_1_2_13_114_1
  doi: 10.2217/fon-2017-0646
– ident: e_1_2_13_85_1
  doi: 10.1007/s00262-020-02493-z
– ident: e_1_2_13_106_1
  doi: 10.1056/NEJMoa1509277
– ident: e_1_2_13_111_1
  doi: 10.1016/j.ejmech.2019.111682
– ident: e_1_2_13_25_1
  doi: 10.1016/j.lungcan.2022.03.005
– ident: e_1_2_13_42_1
  doi: 10.1136/jitc-2020-001395
– ident: e_1_2_13_59_1
  doi: 10.1093/annonc/mdt107
– ident: e_1_2_13_54_1
  doi: 10.1056/NEJMoa1709684
SSID ssj0009630
Score 2.4006517
SecondaryResourceType review_article
Snippet ABSTRACT Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs...
Tumor immunotherapy includes bispecific antibodies (BsAbs), immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell immunotherapy. BsAbs belong to the...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e70011
SubjectTerms Antibodies
Antibodies, Bispecific - immunology
Antibodies, Bispecific - pharmacology
Antibodies, Bispecific - therapeutic use
antibody−drug conjugates
Anticancer properties
Antigen (tumor-associated)
Antitumor activity
Bispecific antibodies
Cancer
Cancer immunotherapy
Conjugates
Conjugation
CTLA-4 protein
Drug development
Effectiveness
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - pharmacology
Immune Checkpoint Inhibitors - therapeutic use
Immune response
Immunoconjugates - pharmacology
Immunoconjugates - therapeutic use
Immunosuppressive agents
Immunotherapy
In vivo methods and tests
Inhibitors
Monoclonal antibodies
Neoplasms - drug therapy
Neoplasms - immunology
Neoplasms - therapy
PD-L1 protein
Pembrolizumab
Side effects
Solid tumors
tumor heterogeneity
Title Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcbf.70011
https://www.ncbi.nlm.nih.gov/pubmed/39463028
https://www.proquest.com/docview/3149110174
https://www.proquest.com/docview/3121280756
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqSgguUMqj2xZkEAcOzTaJ3Tzg1C6sWg4IVVTqASmyHbuEUqfaJIfyC3ruT-wvYcZOUpWHhLhFythO7BnP2DPzDSGvcqZAE-g0EKExAee5CfJURQHotkgaE6KnDaMtPib7R_zD8c7xEnk75MJ4fIjxwg0lw-3XKOBCNts3oKFKmik6TfHog7FaaBAd3kBHAWP19yssSHjGB1ShMN4eW97WRb8ZmLftVadw5g_Il-FTfZzJ6bRr5VT9-AXF8T__ZYXc7w1Ruus55yFZ0naV3PGlKS9Wyd3ZUAnuEbnaqzAhE4OK6K5tK1lj6OEWPcDcEk2BUp2e15Vt6YH9WskKC_hsUWHLgfri-vLq3aI7obPafuvw4q6h_V5rTxxR253Vi6HDQx-3q5s30Hdf66Vx_X1a1C41tHlMjubvP8_2g76WQ6BYlsHa85gLs5MwFpUKXXUCmCcUXIO9ACpRmsiAKk2xPFlpdJ6WEkhYriW0MFoI9oQs29rqNUKTVKdlGMlIy4zLXGdpbkKZhcJkkYqNmpDXw6oWqgc6x3ob3wsP0RwXMN2Fm-4JeTmSnnt0jz8RbQ6sUfQC3hQMTpYRbmd8Ql6Mr2Fd0N8irK47pAG7AMGekwl56llqHIXlHBg0zuBjHWP8ffhitjd3D-v_TrpB7sVgfPmwm02y3C46_QyMp1Y-d1LyE5DxFtY
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRahceJTXQoGAOHBotkns5oG4tFtWu1AqVLVSL1VkO3YJBafaJIfyCzj3J_JLmMmrKg8JcYuUsZ3YM57xeOYbgJcJU6gJdOQKzxiX88S4SaR8F3WbL43x6KaNoi32wtkhf3e0ebQEb_pcmBYfYnC4kWQ0-zUJODmkNy5RQ5U0Y7o1xbPPNaroTWK5s38JHoWs1XlYmBvymPe4Ql6wMTS9qo1-MzGvWqyNypneguP-Y9tIk9NxXcmx-vYLjuP__s1tuNnZos5Wyzx3YEnbVbjeVqc8X4WVSV8M7i5cbOeUk0lxRc6WrXJZUPThujOn9BLtIKU6PStyWzlz-ymXOdXwWXeEzXrq8x_fL3YW9YkzKeznmnx3pdNtt_akIarqr8Wi73C_Dd3V5Wvsuyv3Ujb9fVwUTXZoeQ8Op28PJjO3K-fgKhbHuPw84MJshoz5maLbOoH84wmu0WRArSiNb1CbRlShLDM6iTKJJCzRElsYLQS7D8u2sPohOGGko8zzpa9lzGWi4ygxnow9YWJfBUaN4FW_rKnqsM6p5MaXtEVpDlKc7rSZ7hG8GEjPWoCPPxGt9byRdjJepgwPlz7taHwEz4fXuC505SKsLmqiQdOA8J7DETxoeWoYhSUcOTSI8WMbzvj78Olke9o8PPp30mewMjv4sJvuzvfeP4YbAdpibRTOGixXi1o_QVuqkk8bkfkJ26ga7w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRTwuPMproUBAHDg02yR284BTu8uqC6iqKir1UCmKHbuEgrPaJIfyCzj3J_JLmHEeVXlIiFukjO3EnvGMPTPfALxMmERNoCI387R2OU-0m0TSd1G3-UJrjzxtFG2xF-4e8ndHW0cr8KbPhWnxIYYLN5IMu1-TgC9yvXkBGiqFHpPTFI8-V3joxXTymh5cYEchZ3UXLMwNecx7WCEv2ByaXlZGv1mYlw1Wq3Fmt-C4_9Y20OR03NRiLL_9AuP4nz9zG252lqiz3bLOHVhRZg2utrUpz9bg-qQvBXcXzncKysikqCJn29SFKCn2cMOZU3KJcpBSni7KwtTO3HwqREEVfDaczOQ99dmP7-fTZXPiTErzuaGbu8rpNltzYonq5mu57Ds8aAN3VfUa--6KvVS2v_1laXNDq3twOHv7cbLrdsUcXMniGBefBzzTWyFjfi7JV5ch93gZV2gwoE4U2teoSyOqT5ZrlUS5QBKWKIEttMoydh9WTWnUQ3DCSEW55wtfiZiLRMVRoj0Re5mOfRloOYJX_aqmskM6p4IbX9IWozlIcbpTO90jeDGQLlp4jz8RrfeskXYSXqUMj5Y-7Wd8BM-H17gu5HDJjCobokHDgNCewxE8aFlqGIUlHBk0iPFjLWP8ffh0sjOzD4_-nfQZXNufztIP8733j-FGgIZYG4KzDqv1slFP0JCqxVMrMD8Bm9kZpw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bispecific+Antibodies%2C+Immune+Checkpoint+Inhibitors%2C+and+Antibody-Drug+Conjugates+Directing+Antitumor+Immune+Responses%3A+Challenges+and+Prospects&rft.jtitle=Cell+biochemistry+and+function&rft.au=Li%2C+Chen+Lu&rft.au=Ma%2C+Xin+Yuan&rft.au=Yi%2C+Ping&rft.date=2024-12-01&rft.issn=1099-0844&rft.eissn=1099-0844&rft.volume=42&rft.issue=8&rft.spage=e70011&rft_id=info:doi/10.1002%2Fcbf.70011&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0263-6484&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0263-6484&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0263-6484&client=summon